Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

574 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Who will benefit from treatment against EGFR?
Arribas J, Baselga J. Arribas J, et al. Among authors: baselga j. Lancet Oncol. 2005 May;6(5):257-8. doi: 10.1016/S1470-2045(05)70142-X. Lancet Oncol. 2005. PMID: 15863372 No abstract available.
The EGFR as a target for anticancer therapy--focus on cetuximab.
Baselga J. Baselga J. Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22. doi: 10.1016/s0959-8049(01)00233-7. Eur J Cancer. 2001. PMID: 11597400 Review.
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J. Baselga J. Oncology. 2001;61 Suppl 2:14-21. doi: 10.1159/000055397. Oncology. 2001. PMID: 11694783 Review.
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
Mendelsohn J, Baselga J. Mendelsohn J, et al. Among authors: baselga j. J Clin Oncol. 2003 Jul 15;21(14):2787-99. doi: 10.1200/JCO.2003.01.504. J Clin Oncol. 2003. PMID: 12860957 Review.
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
Baselga J. Baselga J. J Clin Oncol. 2004 Mar 1;22(5):759-61. doi: 10.1200/JCO.2004.12.903. J Clin Oncol. 2004. PMID: 14990627 No abstract available.
Molecular approach to breast cancer treatment.
Yarden Y, Baselga J, Miles D. Yarden Y, et al. Among authors: baselga j. Semin Oncol. 2004 Oct;31(5 Suppl 10):6-13. doi: 10.1053/j.seminoncol.2004.07.016. Semin Oncol. 2004. PMID: 15490369 Review.
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J, Arteaga CL. Baselga J, et al. J Clin Oncol. 2005 Apr 10;23(11):2445-59. doi: 10.1200/JCO.2005.11.890. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753456 Review.
A review of EGFR targeted therapy.
Baselga J. Baselga J. Clin Adv Hematol Oncol. 2003 Apr;1(4):218-9. Clin Adv Hematol Oncol. 2003. PMID: 16224409 No abstract available.
Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
Baselga J. Baselga J. J Clin Oncol. 2006 May 20;24(15):2225-6. doi: 10.1200/JCO.2005.05.3785. J Clin Oncol. 2006. PMID: 16710019 No abstract available.
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA. Curran D, et al. Among authors: baselga j. J Clin Oncol. 2007 Jun 1;25(16):2191-7. doi: 10.1200/JCO.2006.08.8005. J Clin Oncol. 2007. PMID: 17538164 Clinical Trial.
574 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback